- Investing Ideas
- /
- Global Pharmaceuticals & Biotech Undervalued based on future growth
Global Pharmaceuticals & Biotech Undervalued based on future growth
Results
43
Companies which can be considered undervalued when accounting for expected future growth (PEG under 0.8)
43 companies
Medexus Pharmaceuticals
Market Cap: CA$88.4m
Operates as a pharmaceutical company in Canada and the United States.
MDP
CA$2.66
7D
-6.3%
1Y
16.7%
EZZ Life Science Holdings
Market Cap: AU$95.8m
Engages in formulation, production, marketing, and sale of the health and wellbeing products in Australia, New Zealand, Mainland China, and internationally.
EZZ
AU$2.03
7D
-5.1%
1Y
19.1%
Earth Science Tech
Market Cap: US$55.9m
Together with its subsidies, focuses on health and wellness industry.
ETST
US$0.19
7D
-5.9%
1Y
28.9%
Decibel Cannabis
Market Cap: CA$51.9m
An integrated cannabis company, engages in the cannabis cultivation in Canada.
DB
CA$0.09
7D
-5.3%
1Y
50.0%
Neuphoria Therapeutics
Market Cap: US$15.2m
A clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia.
NEUP
US$8.05
7D
-5.3%
1Y
n/a
Minerva Neurosciences
Market Cap: US$13.1m
A clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases.
NERV
US$1.91
7D
-10.2%
1Y
-34.1%
Oncodesign Precision Medicine Société anonyme
Market Cap: €7.1m
A biopharmaceutical company, engages in the precision medicine business.
ALOPM
€0.39
7D
-25.0%
1Y
-63.2%